k-89

PSMA-1007 is a novel Glu-Ureido-type prostate-specific membrane antigen (PSMA) inhibitor.

MK-8998 is a T-type calcium channel antagonist that may be utilized in the treatment of schizophrenia. However, it has not demonstrated efficacy in treating hospitalized patients with acute psychosis, according to the PANSS scores measured at week four.

GSK-894490A is an agonist of ghrelin receptor. GSK-894490A crosses the blood/brain barrier and elicit pro-cognitive effects.

MK-8970 is an acetal carbonate prodrug of raltegravir with enhanced colonic absorption.

K-8986 is a novel h1-receptor antagonist

MRK-898, an orally active modulator of the GABA(A) receptor, selectively interacts with the α1, α2, α3, and α5 subunits, displaying K i values of 1.2 nM, 1.0 nM, 0.73 nM, and 0.50 nM, respectively. It is noteworthy that the α1-containing receptors of GABA(A) are classified as sedative, whereas receptors containing α2 and or α3 are designated as anxiolytic subtype(s) [1].